Inhibrx (INBX) News Today → Digitizing the $11T commodities sector with one tiny stock (From Resource Stock Digest) (Ad) Free INBX Stock Alerts $34.46 -0.24 (-0.69%) (As of 05:19 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15, 2024 | marketbeat.comInhibrx (NASDAQ:INBX) Sees Unusually-High Trading VolumeInhibrx (NASDAQ:INBX) Sees Strong Trading VolumeMay 10, 2024 | finance.yahoo.comInhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-OffMay 10, 2024 | prnewswire.comInhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-OffMay 9, 2024 | businesswire.comINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXMay 8, 2024 | prnewswire.comInhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated MergerMay 4, 2024 | marketbeat.comRussell Investments Group Ltd. Decreases Stock Position in Inhibrx, Inc. (NASDAQ:INBX)Russell Investments Group Ltd. lowered its position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 5.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 435,450 shares of the company's stock after selling 23,606 shareApril 16, 2024 | msn.comAs more rare disease therapies launch, their prices are risingMarch 30, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Short Interest Down 17.9% in MarchInhibrx, Inc. (NASDAQ:INBX - Get Free Report) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 1,600,000 shares, a decrease of 17.9% from the February 29th total of 1,950,000 shares. Based on an average daily trading volume, of 757,800 shares, the days-to-cover ratio is presently 2.1 days. Currently, 4.5% of the shares of the company are sold short.March 28, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Shares Acquired by Wellington Management Group LLPWellington Management Group LLP grew its holdings in Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 24.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 174,899 shares of the company's stock after acquiring an additionalMarch 18, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Sees Significant Drop in Short InterestInhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the target of a significant decrease in short interest during the month of February. As of February 29th, there was short interest totalling 1,950,000 shares, a decrease of 7.1% from the February 14th total of 2,100,000 shares. Based on an average daily volume of 747,100 shares, the days-to-cover ratio is presently 2.6 days. Currently, 5.5% of the shares of the company are sold short.March 16, 2024 | finance.yahoo.comINBX Apr 2024 50.000 putMarch 16, 2024 | finance.yahoo.comINBX Apr 2024 55.000 callMarch 6, 2024 | marketbeat.comRA Capital Management L.P. Purchases 870,340 Shares of Inhibrx, Inc. (NASDAQ:INBX)RA Capital Management L.P. raised its position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 22.6% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,724,207 shares of the company's stock after purchasMarch 4, 2024 | marketbeat.comFmr LLC Trims Stake in Inhibrx, Inc. (NASDAQ:INBX)Fmr LLC trimmed its stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 14.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,517,595 shares of the company's stock after selling 254,137 shares during thMarch 4, 2024 | marketbeat.comShort Interest in Inhibrx, Inc. (NASDAQ:INBX) Drops By 12.5%Inhibrx, Inc. (NASDAQ:INBX - Get Free Report) saw a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 2,100,000 shares, a drop of 12.5% from the January 31st total of 2,400,000 shares. Based on an average daily trading volume, of 690,000 shares, the short-interest ratio is currently 3.0 days. Approximately 5.9% of the shares of the company are short sold.March 1, 2024 | marketbeat.comEventide Asset Management LLC Purchases New Stake in Inhibrx, Inc. (NASDAQ:INBX)Eventide Asset Management LLC acquired a new position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 434,026 shares of the company's stock, valuedFebruary 29, 2024 | realmoney.thestreet.comInhibrx just downgraded at Jefferies, here's whyFebruary 28, 2024 | finanznachrichten.deInhibrx, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 28, 2024 | prnewswire.comInhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 22, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Shares Sold by Rafferty Asset Management LLCRafferty Asset Management LLC lowered its position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 12.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 115,828 shares of the cFebruary 16, 2024 | marketbeat.comLoomis Sayles & Co. L P Has $20.49 Million Stock Holdings in Inhibrx, Inc. (NASDAQ:INBX)Loomis Sayles & Co. L P decreased its stake in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 3.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,116,484 shares of the company's stock after selling 34,847 shares during the period. Loomis Sayles &February 10, 2024 | businesswire.comINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXFebruary 10, 2024 | businesswire.comINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXJanuary 28, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Short Interest Up 20.3% in JanuaryInhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 4,090,000 shares, a growth of 20.3% from the December 31st total of 3,400,000 shares. Based on an average trading volume of 665,900 shares, the days-to-cover ratio is currently 6.1 days. Approximately 11.5% of the company's stock are short sold.January 25, 2024 | marketbeat.comLifesci Capital Downgrades Inhibrx (NASDAQ:INBX) to Market PerformLifesci Capital cut Inhibrx from an "outperform" rating to a "market perform" rating in a report on Tuesday.January 24, 2024 | msn.comSanofi signs agreement to acquire Inhibrx for $1.7bnJanuary 24, 2024 | finance.yahoo.comBiotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & MoreJanuary 24, 2024 | seekingalpha.comSanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 AcquisitionJanuary 24, 2024 | finance.yahoo.comInhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?January 24, 2024 | realmoney.thestreet.comInhibrx just downgraded at LifeSci Capital, here's whyJanuary 23, 2024 | msn.comThese Stocks Are Moving the Most Today: United, Logitech, Archer Daniels, Inhibrx, J&J, Netflix, and MoreJanuary 23, 2024 | marketwatch.comSanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- UpdateJanuary 23, 2024 | reuters.comFrance's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 blnJanuary 23, 2024 | tmcnet.comINBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to ShareholdersJanuary 23, 2024 | marketbeat.comJMP Securities Reaffirms "Market Perform" Rating for Inhibrx (NASDAQ:INBX)JMP Securities reiterated a "market perform" rating on shares of Inhibrx in a research note on Tuesday.December 9, 2023 | morningstar.comInhibrx Inc Ordinary Shares INBXDecember 2, 2023 | morningstar.comInhibrx Inc Ordinary SharesNovember 10, 2023 | msn.comInhibrx posts Q3 resultsNovember 10, 2023 | finanznachrichten.deInhibrx, Inc.: Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNovember 9, 2023 | finance.yahoo.comInhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNovember 4, 2023 | msn.comInhibrx reports initial Phase I Ewing sarcoma trial dataNovember 2, 2023 | finance.yahoo.comInhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing SarcomaSeptember 19, 2023 | finance.yahoo.comInhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and CanadaSeptember 6, 2023 | marketbeat.comCitigroup Inc. Buys 37,822 Shares of Inhibrx, Inc. (NASDAQ:INBX)Citigroup Inc. lifted its position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 43.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,335 shares of the company's stock after acquirAugust 29, 2023 | marketwatch.comInhibrx Shares Rise 15% After Private Placement FinancingAugust 29, 2023 | finance.yahoo.comInhibrx Announces $200 Million Private Placement FinancingAugust 23, 2023 | markets.businessinsider.comJMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To KnowAugust 23, 2023 | nasdaq.comJMP Securities Maintains Inhibrx (INBX) Outperform RecommendationAugust 23, 2023 | markets.businessinsider.comJMP Securities Reaffirms Their Buy Rating on Inhibrx (INBX)August 21, 2023 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Shares Sold by Barclays PLCBarclays PLC trimmed its holdings in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 39.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,661 shares of the company's stock after selling 41,942 shares d Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Digitizing the $11T commodities sector with one tiny stock (Ad)One tiny company — trading completely undiscovered around 15-cents per share — has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. It’s an opportunity that likely won’t stay at these levels for long INBX Media Mentions By Week INBX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INBX News Sentiment▼0.640.42▲Average Medical News Sentiment INBX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INBX Articles This Week▼11▲INBX Articles Average Week Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CG Oncology News Fusion Pharmaceuticals News Ginkgo Bioworks News Novavax News Sana Biotechnology News Beam Therapeutics News Neumora Therapeutics News ADMA Biologics News Tarsus Pharmaceuticals News Kymera Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INBX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our Partners"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
